Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Wyeth’s pneumococcal vaccine beats expectations

Wyeth’s pneumococcal vaccine beats expectations

3rd April 2007

A vaccine developed to prevent pneumococcal infections is cutting the incidents of common bacterial diseases among both children and adults, reveals new research.

The report’s lead author asserts that the preventive treatment from pharmaceutical firm Wyeth is producing positive results “beyond what it was supposed to do” as it has reduced the number of children suffering from repeat ear infections.

Dr Katherine Poehling from the Wake Forest University Baptist Medical Centre notes that the Prevenar vaccine has cut levels of ear tube insertion procedures since it was launched in the US and Canada seven years ago, reports Reuters.

“We have seen declines in the incidence of serious infections such as pneumococcal meningitis in both children and adults, as well as the number of children developing frequent ear infections,” says Dr Poehling.

Published in Paediatrics, the study involved the collation of data from over 150,000 children in the state of Tennessee and a further 26,400 infants aged between one month and five years in New York.

The vaccination is given to children when they are two, four and six months old.

Last month, Wyeth welcomed the decision from the World Health Organisation to back the inclusion of the pneumococcal conjugate vaccine in global immunisation schemes.

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.